Biotech · Nasdaq
Amgen
Price data: TradingView widget below
Amgen (AMGN) — Amgen is one of the biggest biotech companies, making medicines for bone health, cancer, inflammation and heart disease, plus biosimilars.
Loading chart…
Open AMGN chart in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
Loading chart…
📐 Technicals
Loading chart…
Indicator summary from TradingView (moving averages, oscillators). A mechanical signal, not advice.
Open technicals in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
📊 Fundamentals
Loading chart…
🏢 Company profile
Loading chart…
📰 Latest AMGN news
Loading chart…
🧩 What it is
Amgen is one of the biggest biotech companies, making medicines for bone health, cancer, inflammation and heart disease, plus biosimilars.
⚡ Why it's interesting
It's a mature biotech with real profits and a dividend. Investors watch its obesity-drug programme closely.
⚠️ Key risks
Patents expire and cheaper biosimilars eat sales. Drug trials can fail, and US drug-pricing policy can cut revenue. It has debt from acquisitions such as Horizon.
👀 What to watch
obesity-drug trial results, biosimilar competition and US drug-price policy. Pipeline news can move it sharply. Dividend investors also watch whether payouts keep growing.
Written by the Hodlia.fi editorial team. Education only — not financial advice, no price predictions. Contains a TradingView affiliate link.
❓ Amgen FAQ
What is Amgen (AMGN)?
Amgen is one of the biggest biotech companies, making medicines for bone health, cancer, inflammation and heart disease, plus biosimilars.
Why do people follow Amgen?
It's a mature biotech with real profits and a dividend. Investors watch its obesity-drug programme closely.
What are the main risks of Amgen?
Patents expire and cheaper biosimilars eat sales. Drug trials can fail, and US drug-pricing policy can cut revenue. It has debt from acquisitions such as Horizon.
What should I watch with Amgen?
obesity-drug trial results, biosimilar competition and US drug-price policy. Pipeline news can move it sharply. Dividend investors also watch whether payouts keep growing.
Is Amgen a good investment?
Hodlia не надає інвестиційних порад. Чи підходить вам Amgen, залежить від ваших цілей, горизонту та того, яку втрату ви можете витримати. Окремі акції можуть сильно впасти навіть на спокійному ринку. Прочитайте ризики вище, порівняйте з диверсифікованою альтернативою та зверніться по незалежну пораду.